Here’s what you need to know.
1. Allergan received the rights to preclinical compounds ABI-M201 and ABI-M301 targeting ulcerative colitis and Crohn’s disease. Allergan also received rights to two compounds targeting various forms of irritable bowel syndrome.
2. Allergan will pay $50 million to Assembly. Assembly will also hold various different types of royalties.
3. The transaction should close in the first quarter of 2017.
More articles on gastroenterology/endoscopy:
GI leader to know: Dr. Bitman Stewart of Digestive Care
Integrated Endoscopy seeks $4.4M for executive compensation: 3 key notes
Hallmark Health Medical Associates names gastroenterologist Dr. Michael Newman president: 3 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
